Phase Ⅱ trial of granulocyte-macrophage colony-stimulating factor plus thalidomide in older patients with castration-resistant prostate cancer

Song,Lei; Zhou,Xijian; Li,Xiangyong

doi:10.3892/mco.2015.571

July-2015 Volume 3 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

July-2015 Volume 3 Issue 4

Full Size Image

Article

Phase Ⅱ trial of granulocyte-macrophage colony-stimulating factor plus thalidomide in older patients with castration-resistant prostate cancer

Authors:
- Lei Song
- Xijian Zhou
- Xiangyong Li
View Affiliations / Copyright

Affiliations: Department of Hematology and Oncology, The 101th Hospital of The People's Liberation Army, Wuxi, Jiangsu 214044, P.R. China
Pages: 865-868
|
Published online on: May 15, 2015

https://doi.org/10.3892/mco.2015.571
Expand metrics +

Abstract

The objective of this study was to assess the efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with thalidomide for prostate-specific antigen (PSA) reduction in older patients (aged ≥70 years, life expectancy of >1 year) with castration‑resistant prostate cancer (CRPC). A total of 11 CRPC patients were treated with 300 µg GM‑CSF administered subcutaneously on days 1, 3 and 6 of weeks 1 and 2 of each cycle. Thalidomide was gradually increased to reach the study dose of 100 mg̸day. The patients were assessed every 4 weeks with therapy continuing to 4 months. All 11 patients exhibited a decrease in PSA levels and 3 patients (27.2%) exhibited a PSA decrease of >50% in cycle 1. In cycle 2, 8 patients exhibited decreasing PSA levels. A total of 3 patients (27.2%) had a PSA rebound, with 1 patient exhibiting a PSA rebound of >50%. In cycle 3, 10 patients exhibited continuously decreasing PSA levels, with 2 patients (18.2%) exhibiting a PSA decrease of >50%; 1 patient (27.2%) had a PSA rebound of <50%. In cycle 4, 9 patients exhibited continuously decreasing PSA levels and 2 patients (18.2%) had a PSA rebound of >50%. all 11 patients in this study exhibited a decrease in PSA levels, with a median decrease of 92.2%. Therapy was well tolerated, with the majority of the patients experiencing only one adverse event. In conclusion, the combination of GM‑CSF with thalidomide was found to be clinically effective and well tolerated by elderly CRPC patients. Therefore, GM‑CSF plus thalidomide may be considered a viable treatment option for such patients.

View Figures

View References

1	Loblaw DA, Virgo KS, Nam R, et al: Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol. 25:1596–1605. 2007. View Article : Google Scholar : PubMed/NCBI
2	Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 351:1502–1512. 2004. View Article : Google Scholar : PubMed/NCBI
3	Bissery MC, Vrignaud P and Bayssas M: Preclinical in vivo activity of docetaxel containing combinations. Proc Am Soc Clin Oncol. 14:4891995.
4	Kantoff PW, Higano CS, Shore ND, et al: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 363:411–422. 2010. View Article : Google Scholar : PubMed/NCBI
5	Dreicer R, Klein EA, Elson P, et al: Phase II trial of GM-CSF thalidomide in patients with androgen-independent metastatic prostate cancer. Urol Oncol. 23:82–86. 2005. View Article : Google Scholar : PubMed/NCBI
6	Franks ME, Macpherson GR and Figg WD: Thalidomide. Lancet. 363:1802–1811. 2004. View Article : Google Scholar : PubMed/NCBI
7	D'Amato RJ, Loughnan MS, Flynn E, et al: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 91:4082–4085. 1994. View Article : Google Scholar : PubMed/NCBI
8	Drake MJ, Robson W, Mehta P, et al: An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer. 88:822–827. 2003. View Article : Google Scholar : PubMed/NCBI
9	Figg WD, Dahut W, Duray P, et al: A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res. 7:1888–1893. 2001.PubMed/NCBI
10	Small EJ, Reese DM, Um B, et al: Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Can Res. 5:1738–1744. 1999.
11	Rini B, Weinberg V, Bok R and Small EJ: Prostate-speciﬁc antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. J Clin Oncol. 21:99–105. 2003. View Article : Google Scholar : PubMed/NCBI
12	Rini BI, Fong L, Weinberg V, Kavanaugh B and Small EJ: Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor. J Urol. 75:2087–2091. 2006. View Article : Google Scholar
13	Amato RJ, Hernandez-McClain J and Henary H: Phase 2 study of granulocyte-macrophage colony-stimulating factor plus thalidomide in patients with hormone-naïve adenocarcinoma of the prostate. Urol Oncol. 27:8–13. 2009. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Phase Ⅱ trial of granulocyte-macrophage colony-stimulating factor plus thalidomide in older patients with castration-resistant prostate cancer

This article is mentioned in:

Abstract

Figure 1

Related Articles